Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796806 · ClinicalTrials.gov registry record
Methods Validation Assessment for Study of Inflammatory Skin Disease
A clinical trial of Lichen Planus, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT03796806 is a study of Lichen Planus that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 142-participant average among 3 other Lichen Planus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03796806, a study of Lichen Planus, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
1. Assess validity of methods involved in molecular studies of the skin in inflammatory skin disease 2. Assess feasibility of methods for grafting fresh human skin (normal and diseased with inflammatory skin disease) onto an established xenograft murine model.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2019-01-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796806
The ClinicalTrials.gov registry entry for NCT03796806 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 3 other Lichen Planus trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lichen Planus appearing as the primary indexed condition, and to 0 interventions.
NCT03796806 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03796806 about?
NCT03796806 is a clinical study titled "Methods Validation Assessment for Study of Inflammatory Skin Disease". 1. Assess validity of methods involved in molecular studies of the skin in inflammatory skin disease 2. Assess feasibility of methods for grafting fresh human skin (normal and diseased with inflammatory skin disease) onto an established xenograft murine model.
What is the current status of trial NCT03796806?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2019-01-14. Estimated completion is 2019-01-14.
What conditions does trial NCT03796806 study?
This clinical trial studies the following conditions: Lichen Planus.
Who is sponsoring clinical trial NCT03796806?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796806 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Planus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
ACTIVE NOT RECRUITING · NA
-
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
COMPLETED · Early Phase 1
-
Biomarkers for Oral Cancer
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.